170 related articles for article (PubMed ID: 21443285)
1. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
Drugs; 2011 Mar; 71(5):625-49. PubMed ID: 21443285
[TBL] [Abstract][Full Text] [Related]
2. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I; Walter-Croneck A; Magen H; Mateos MV; Belch A; Reece D; Beksac M; Bleickardt E; Poulart V; Sheng J; Sy O; Katz J; Singhal A; Richardson P
Br J Haematol; 2017 Sep; 178(6):896-905. PubMed ID: 28677826
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
5. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Leleu X; Kyriakou C; Vande Broek I; Murphy P; Bacon P; Lewis P; Gilet H; Arnould B; Petrucci MT
Blood Cancer J; 2017 Mar; 7(3):e543. PubMed ID: 28304402
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Lehne M; Kortüm KM; Ramasamy K; Zamagni E; d'Estrubé T; Zhuleku E; Hanna M; Shukla S; Ghiani M; Maywald U; Wilke T; Kellermann L; Perera S
Eur J Haematol; 2024 May; 112(5):701-713. PubMed ID: 38146208
[TBL] [Abstract][Full Text] [Related]
7. Aponermin: First Approval.
Dhillon S
Drugs; 2024 Apr; 84(4):459-466. PubMed ID: 38441805
[TBL] [Abstract][Full Text] [Related]
8. The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.
Schmitz S; Maguire Á; Morris J; Ruggeri K; Haller E; Kuhn I; Leahy J; Homer N; Khan A; Bowden J; Buchanan V; O'Dwyer M; Cook G; Walsh C
BMC Med Res Methodol; 2018 Jun; 18(1):66. PubMed ID: 29954322
[TBL] [Abstract][Full Text] [Related]
9. Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial.
White DJ; Paul N; Macdonald DA; Meyer RM; Shepherd LE
Curr Oncol; 2007 Apr; 14(2):61-5. PubMed ID: 17576467
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib: the evidence of its clinical impact in multiple myeloma.
Lancaster S
Core Evid; 2006; 1(4):265-77. PubMed ID: 22496681
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide-induced eosinophilic pneumonia.
Toma A; Rapoport AP; Burke A; Sachdeva A
Respirol Case Rep; 2017 Jul; 5(4):e00233. PubMed ID: 28451433
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.
van Nieuwenhuijzen N; Frunt R; May AM; Minnema MC
Blood Cancer J; 2021 Mar; 11(3):44. PubMed ID: 33649328
[TBL] [Abstract][Full Text] [Related]
13. Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature.
Win H; Gowin K
Clin Case Rep; 2020 Dec; 8(12):3043-3049. PubMed ID: 33363876
[TBL] [Abstract][Full Text] [Related]
14. Maintain maintenance in multiple myeloma?
Zweegman S; van de Donk NWJC
Blood; 2023 Nov; 142(18):1501-1502. PubMed ID: 37917081
[No Abstract] [Full Text] [Related]
15. Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma.
Raedler LA
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):140-3. PubMed ID: 27668061
[No Abstract] [Full Text] [Related]
16. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective.
Vandewalle B; Félix J; Almeida J; Valeska A; Yeo R
Value Health; 2014 Nov; 17(7):A736. PubMed ID: 27202638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
